DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

04 Nov 2019

Y-mAbs Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its public offering of 5,134,750 shares of its common stock, at a public offering price of $28.00 per share, which includes the exercise in full of the underwriters’ option to purchase 669,750 additional shares of common stock. The aggregate gross proceeds to Y-mAbs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $143.8 million. All of the shares of common stock were offered by the Company. Y-mAbs’ common stock is listed on The Nasdaq Global Select Market under the ticker symbol “YMAB.”

Morgan Stanley, J.P. Morgan and BofA Securities acted as the joint book-running managers for the offering. Wedbush PacGrow and H.C. Wainwright & Co. acted as co-managers for the offering.

    If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact ps@danskbiotek.dk or +45 7172 1114

    Copyright 2019 DANISH BIO – DANSK BIOTEK. All rights reserved.